1. MARKETS
  2. SECTOR : PHARMACEUTICALS & BIOTECHNOLOGY
  3. INDUSTRY : PHARMACEUTICALS
  4. GLENMARK PHARMACEUTICALS LTD.

Glenmark Pharmaceuticals Ltd.

NSE: GLENMARK | BSE: 532296

Expensive Performer
Download real time

1378.10 1.80 (0.13%)

39.88% Gain from 52W Low

671.1K NSE+BSE Volume

NSE 11 Apr, 2025 3:31 PM (IST)

Watchlist

Portfolio

Alert

Share
9S
10W
3O
1T
38,888.4

Market Cap

High in industry
-221.2

PE TTM

Negative PE TTM
-2.8

PEG TTM

PEG TTM is negative
4.6

Price to Book

Above industry Median
1.0

Beta 1Year

Average volatility


Board Meetings - Glenmark Pharmaceuticals Ltd.

The latest board meeting for Glenmark Pharmaceuticals Ltd. took place on 14 Feb 2025, for the purpose of Quarterly Results

Share
Ex-date Purpose Notes
14 Feb 2025 Quarterly Results -
14 Nov 2024 Quarterly Results -
14 Aug 2024 Quarterly Results -
24 May 2024 Audited Results & Final Dividend -
14 Feb 2024 Quarterly Results -
10 Nov 2023 Quarterly Results -
11 Aug 2023 Quarterly Results -
19 May 2023 Audited Results & Final Dividend -
10 Feb 2023 Quarterly Results -
11 Nov 2022 Quarterly Results -
10 Aug 2022 Quarterly Results -
27 May 2022 Audited Results & Final Dividend -
11 Feb 2022 Quarterly Results -
12 Nov 2021 Quarterly Results -
13 Aug 2021 Quarterly Results -
28 May 2021 Audited Results & Final Dividend -
12 Feb 2021 Quarterly Results & Others Inter alia, , to consider opportunistic tenders or buybacks of any part of its Singapore listed foreign currency convertible bonds, being, its U.S.$200 million
06 Nov 2020 Quarterly Results -
14 Aug 2020 Quarterly Results -
26 Jun 2020 Audited Results & Dividend -
14 Feb 2020 Quarterly Results & Others inter-alia, consider and evaluate proposals for raising of funds either by issuance of bonds / debentures / non-convertible debt instruments or any other securities or any combination thereof,
14 Nov 2019 Quarterly Results -
13 Aug 2019 Quarterly Results -
29 May 2019 Others -
14 Feb 2019 Quarterly Results -
13 Nov 2018 Quarterly Results -
28 Sep 2018 Others To consider opportunistic tenders or buybacks of any part of its Singapore listed foreign currency convertible bonds.
10 Aug 2018 Quarterly Results -
29 May 2018 Audited Results & Dividend -
08 Feb 2018 Quarterly Results -
02 Nov 2017 Quarterly Results -
27 Jul 2017 Quarterly Results -
11 May 2017 Audited Results -
02 Feb 2017 Quarterly Results -
27 Oct 2016 Quarterly Results -
12 Aug 2016 Quarterly Results -
12 May 2016 Audited Results & Dividend -
28 Jan 2016 Quarterly Results -
29 Oct 2015 Quarterly Results -
30 Jul 2015 Quarterly Results -
29 May 2015 Audited Results & Dividend -
12 Feb 2015 Quarterly Results -
30 Oct 2014 Quarterly Results -
24 Jul 2014 Quarterly Results -
08 May 2014 Audited Results & Dividend -
24 Jan 2014 Quarterly Results -
31 Oct 2013 Quarterly Results -
01 Aug 2013 Quarterly Results -
07 May 2013 Audited Results & Dividend -
29 Jan 2013 Quarterly Results -
30 Oct 2012 Quarterly Results -
02 Aug 2012 Quarterly Results -
08 May 2012 Audited Results, Dividend & ESOP Employees Stock Option Plan.
30 Jan 2012 Quarterly Results -
09 Nov 2011 Quarterly Results -
26 Jul 2011 Quarterly Results -
10 May 2011 Audited Results & Dividend -
01 Feb 2011 Quarterly Results -
27 Oct 2010 Quarterly Results -
24 Aug 2010 Allotment of Shares The Board has allotted 38,000 Shares to the Employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
27 Jul 2010 Quarterly Results -
28 May 2010 Audited Results & Dividend -
29 Jan 2010 Quarterly Results & ESOP The Board has allotted 59,200 Shares to the Employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
29 Oct 2009 Quarterly Results & Others The Board has approved the conversion of 64,100 stock options issued to its Employees into 64,100 Equity Shares pursuant to the ESOS 2003.
14 Aug 2009 Appointment of Additional Director's The Board appointed Mr. D R Mehta & Mrs. B E Saldanha as Additional Director of the Company.
27 Jul 2009 Quarterly Results & Others To raise the funds through issue of Equity Shares /GDRs/ADRs/FCCBs & / or such other securities for an amt. not exceeding US$ 250 million & to convert 84,000 stock options issued to its employees.
26 Jun 2009 Audited Results, Dividend & Others Inter alia, to allot 25,800 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
17 Apr 2009 Allotment of Shares to the Employees Inter alia, to allot 7,000 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
27 Jan 2009 Quarterly Results -
27 Oct 2008 Quarterly Results -
11 Aug 2008 Employees Stock Option Plan To allot 1,000 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
28 Jul 2008 Quarterly Results & Others To allot 81,100 shares to the employees of the Company on exercise of options granted to them pursuant to ESOS 2003.
28 Apr 2008 Audited Results -
21 Jan 2008 Quarterly Results -
31 Oct 2007 Quarterly Results & Interim Dividend -
30 Jul 2007 Quarterly Results -
11 Jun 2007 Stock Split -
25 Apr 2007 Audited Results -
23 Jan 2007 Quarterly Results -
26 Dec 2006 Interim Dividend -
31 Oct 2006 Quarterly Results -
31 Jul 2006 Quarterly Results -
28 Apr 2006 Accounts -
31 Jan 2006 Quarterly Results & Interim Dividend -
31 Oct 2005 Quarterly Results -
29 Jul 2005 Quarterly Results -
04 Jul 2005 Employees Stock Option Plan were converted into 10,000 Equity shares to the employees of the Company.
27 Apr 2005 Quarterly Results -
26 Apr 2005 Interim Dividend -
18 Mar 2005 Allotment of Bonus Shares -
27 Jan 2005 Quarterly Results -
06 Jan 2005 Bonus issue -
11 Dec 2004 Others To consider issue of Foreign currency convertible bonds.
25 Oct 2004 Quarterly Results -
22 Jul 2004 Quarterly Results -
22 Apr 2004 Quarterly Results -
29 Mar 2004 Interim Dividend To consider Investment in India & abroad
31 Jan 2004 Quarterly Results -
24 Oct 2003 Quarterly Results -
29 Sep 2003 Others To consider and approve the conversion of Debentures issued to CDC Financial Services (Mauritius) Ltd. and South Asia Regional Fund into equity shares.